




ITRACONAZOLE PRACTICE INSIGHTS

OPTIMIZING DERMATOPHYTOSIS CARE: A COMPREHENSIVE APPROACH WITH CONVENTIONAL AND SUPRA BIOAVAILABLE ITRACONAZOLE



CUTANEOUS DERMATOPHYTOSIS: A COMMON PRESENTATION IN ROUTINE PRACTICE

Around **30%** of dermatologists
report a prevalence range of


40-60%



BURDEN OF RECALCITRANT DERMATOPHYTOSIS

Approximately **39%** of
dermatologists reported a range of
20-40%
recalcitrant cases

14% indicated a
range of
40-60%



DRUGS OF CHOICE: EMPOWERING THE FIGHT

For naive cases, **93%**
of dermatologists prefer
ORAL ITRACONAZOLE
as the drug of choice



For recalcitrant cases, **77%**
of dermatologists still rely
on **ORAL ITRACONAZOLE**,
highlighting its significance

CONVENTIONAL ITRACONAZOLE: DOSAGE AND DURATION

- **37%** of dermatologists prescribe **100 mg BD**,
33% choose **200 mg OD**
- Treatment duration ranges from **4 weeks to 8 weeks** for majority of dermatologists



CHALLENGES WITH CONVENTIONAL ITRACONAZOLE



Non-responsiveness in



30% of patients



SUPRA BIOAVAILABLE ITRACONAZOLE: A NOVEL SOLUTION

Dermatologists have observed
better responses with supra bioavailable itraconazole,
with **70%** noting **positive results in**
non-responsive cases

EMBRACING INNOVATION FOR BETTER OUTCOMES

55% of dermatologists utilize **supra bioavailable itraconazole** in
>20% of dermatophytosis cases

For naive cases,
30% choose
supra bioavailable
itraconazole
in **>25%** of treatments



In recalcitrant cases,
46% of dermatologists
prescribe
supra bioavailable
itraconazole
in **>50%** of cases



PREFERRED DOSAGE AND DURATION OF SUPRA BIOAVAILABLE ITRACONAZOLE

Almost **54%** of dermatologists prescribe
130 mg OD/BD

39% of dermatologists recommend treatment
duration of **2-4 weeks**

TAKE-HOME POINTS

- Recalcitrant dermatophytosis cases, which are resistant to conventional treatments, pose a considerable burden in dermatological practice.
- Systemic antifungals, especially oral itraconazole, are the drugs of choice for dermatophytosis treatment in both naive and recalcitrant cases.
- Around 30% of patients do not respond to conventional itraconazole, indicating the need for more effective alternatives.
- Supra bioavailable itraconazole emerges as a novel and promising option, with a substantial number of dermatologists reporting positive outcomes in non-responsive cases.
- Usage of supra bioavailable itraconazole is rising among dermatologists, particularly in recalcitrant cases, showing its potential as an innovative and effective therapeutic option.

Source: Data on File. Survey among 43 dermatologists across India. Cipla Ltd.



For any further information, please contact:
Cipla Ltd., Regd. Office: Cipla House,
Peninsula Business Park, Ganpatrao Kadam Marg,
Lower Parel, Mumbai - 400013, India.
www.cipla.com